ArticleFrontiers in oncology2025

Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma-importance of pre-CAR-T optimization.

Phoebe Joy Ho et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.